Trials / Unknown
UnknownNCT05502705
The Effect of Intravenous Lidocaine on Postoperative Cognitive Function in Elderly Patients
Effects of Intravenous Lidocaine on Serum BDNF, NGF, miRNA-206 and miRNA-98 in Elderly Patients Undergoing Abdominal Surgery Under General Anesthesia
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- General Hospital of Ningxia Medical University · Academic / Other
- Sex
- All
- Age
- 65 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the efficacy of intravenous lidocaine on BDNF, NGF, miRNA-206 and miRNA-98 in serum in elderly patients undergoing abdominal surgery under general anesthesia.
Detailed description
Postoperative cognitive dysfunction (POCD) is a major complication following surgeries and anesthesia, especially in elderly individuals. Lidocaine, an inexpensive, widely available, and relatively safe compound, is a local anesthetic that readily crosses the blood-brain barrier. Intravenous lidocaine can reduce the incidence of POCD. However, the mechanism is still unclear. Brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), which are regulated by miRNA-206 and miRNA-98 respectively, play a key role in learning, memory, and cognition. Previous studies have shown that the levels of BDNF and NGF can be improved by lidocaine. The objective of this study is to investigate the efficacy of intravenous lidocaine on the incidence of early POCD, and the levels of BDNF, NGF, miRNA-206 and miRNA-98 in elderly patients undergoing abdominal surgery under general anesthesia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lidocaine | Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the frst hour, 1.5 mg/kg for the second hour, 0.7 mg/kg until the end of the surgery |
| OTHER | Normal saline (NS) | Patients are received equal volumes of saline intravenously until the end of the surgery |
Timeline
- Start date
- 2022-09-01
- Primary completion
- 2024-09-01
- Completion
- 2024-12-01
- First posted
- 2022-08-16
- Last updated
- 2022-08-16
Source: ClinicalTrials.gov record NCT05502705. Inclusion in this directory is not an endorsement.